Published online before print January 19, 2004, doi: 10.1161/01.CIR.0000109697.68832.5D
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:513-519.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors
From the Bristol Heart Institute, Bristol Royal Infirmary, Bristol (S.J.W., E.D.P.), and the Division of Cardiovascular and Medical Sciences, University of Glasgow (S.A.N., M.J.B., A.H.B.), UK; and the Laboratorium für Molekulare Biologie, Genzentrum, Ludwig-Maximilians Universität München (H.B., K.L., M.H.), the Medizinische Klinik III, Klinikum der Universität München (M.H.), and Gesellshaft für Strahelforschung (M.H.), Munich, Germany.
Correspondence to Dr A.H. Baker, Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G11 6NT UK. E-mail ab11f{at}clinmed.gla.ac.uk
Received May 9, 2003; de novo received August 12, 2003; revision received September 23, 2003; accepted September 25, 2003.
Background— Gene therapy offers an unprecedented opportunity to treat diverse pathologies. Adeno-associated virus (AAV) is a promising gene delivery vector for cardiovascular disease. However, AAV transduces the liver after systemic administration, reducing its usefulness for therapies targeted at other sites. Because vascular endothelial cells (ECs) are in contact with the bloodstream and are heterogeneous between organs, they represent an ideal target for site-specific delivery of biological agents.
Methods and Results— We isolated human venous EC-targeting peptides by phage display and genetically incorporated them into AAV capsids after amino acid 587. Peptide-modified AAVs transduced venous (but not arterial) ECs in vitro, whereas hepatocyte transduction was significantly lower than with native AAV. Intravenous infusion of engineered AAVs into mice produced reduced vector accumulation in liver measured 1 hour and 28 days after injection and delayed blood clearance rates compared with native AAV. Peptide-modified AAVs produced enhanced uptake of virions in the vena cava with selective transgene expression. Retargeting was dose dependent, and coinfusion of either heparin or free competing peptides indicated that uptake was principally independent of native AAV tropism and mediated via the peptide.
Conclusions— AAV tropism can be genetically engineered by use of phage display–derived peptides to generate vectors that are selective for the vasculature.
Key Words: gene therapy • endothelium • viruses • peptides
This article has been cited by other articles:
 |
|
 |
|
  M. Trepel, C. A. Stoneham, H. Eleftherohorinou, N. D. Mazarakis, R. Pasqualini, W. Arap, and A. Hajitou A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer Mol. Cancer Ther., August 1, 2009; 8(8): 2383 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Daya and K. I. Berns Gene Therapy Using Adeno-Associated Virus Vectors Clin. Microbiol. Rev., October 1, 2008; 21(4): 583 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Grimm, J. S. Lee, L. Wang, T. Desai, B. Akache, T. A. Storm, and M. A. Kay In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses J. Virol., June 15, 2008; 82(12): 5887 - 5911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Perabo, D. Goldnau, K. White, J. Endell, J. Boucas, S. Humme, L. M. Work, H. Janicki, M. Hallek, A. H. Baker, et al. Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism J. Virol., July 15, 2006; 80(14): 7265 - 7269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vasileva, R. M. Linden, and R. Jessberger Homologous recombination is required for AAV-mediated gene targeting Nucleic Acids Res., July 5, 2006; 34(11): 3345 - 3360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu and A. Deisseroth Tumor vascular targeting therapy with viral vectors Blood, April 15, 2006; 107(8): 3027 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Muller, B. Leuchs, S. T. Pleger, D. Grimm, W.-M. Franz, H. A. Katus, and J. A. Kleinschmidt Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors Cardiovasc Res, April 1, 2006; 70(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Lochrie, G. P. Tatsuno, B. Christie, J. W. McDonnell, S. Zhou, R. Surosky, G. F. Pierce, and P. Colosi Mutations on the External Surfaces of Adeno-Associated Virus Type 2 Capsids That Affect Transduction and Neutralization J. Virol., January 15, 2006; 80(2): 821 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nakai, S. Fuess, T. A. Storm, S.-i. Muramatsu, Y. Nara, and M. A. Kay Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice J. Virol., January 1, 2005; 79(1): 214 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Baker, A. Kritz, L. M. Work, and S. A. Nicklin Cell-selective viral gene delivery vectors for the vasculature Exp Physiol, January 1, 2005; 90(1): 27 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sharif, K. Daly, J. Crowley, and T. O'Brien Current status of catheter- and stent-based gene therapy Cardiovasc Res, November 1, 2004; 64(2): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Melo, M. Gnecchi, A. S. Pachori, D. Kong, K. Wang, X. Liu, R. E. Pratt, and V. J. Dzau Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1761 - 1774. [Abstract] [Full Text] [PDF]
|
|